Overview
Dr. Li Hu is the investment partner of Stowe Capital's China team, responsible for the management of investee companies, and works closely with the team to evaluate investment opportunities for startups in the field of new drug research and development. 30 has nearly a year of experience in small molecule and antibody drug research and development in the field of oncology and other diseases; is a co-founding team member and core executive of Shanghai Mayak Biotechnology (now a subsidiary of Lapp Biotech), worked at the GlaxoSmithKline Research and Development Center in Philadelphia, and served as a research and development biological consultant at Scinovo. Companies invested and managed include Alternative Bio, Nuclear Ark Medicine, Ray Medicine, and others.
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
李虎博士是斯道资本中国团队的投资合伙人，负责被投企业的管理，并与团队紧密协作评估新药研发领域初创公司的投资机会。在肿瘤及其他疾病领域的小分子和抗体类药物研发方面拥有近30年经验；是上海美雅珂生物技术（现为乐普生物子公司）联合创始团队成员及核心高管，曾任职于费城葛兰素史克研发中心，并在Scinovo担任研发生物顾问。投资并管理的公司包括Alternative Bio、核舟医药、Ray Medicine等。